Barclays’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,922
| Closed | -$275K | – | 5385 |
|
|
2026
Q1 | $275K | Buy |
6,922
+5,814
| +525% | +$149K | ﹤0.01% | 3516 |
|
|
2025
Q4 | $27.7K | Sell |
1,108
-3,860
| -78% | -$97.8K | ﹤0.01% | 4835 |
|
|
2025
Q3 | $120K | Sell |
4,968
-2,551
| -34% | -$45.3K | ﹤0.01% | 4558 |
|
|
2025
Q2 | $98.8K | Sell |
7,519
-30,655
| -80% | -$388K | ﹤0.01% | 4572 |
|
|
2025
Q1 | $549K | Buy |
38,174
+32,872
| +620% | +$538K | ﹤0.01% | 3474 |
|
|
2024
Q4 | $88.8K | Buy |
5,302
+4,952
| +1,415% | +$82K | ﹤0.01% | 4623 |
|
|
2024
Q3 | $5.6K | Buy |
+350
| New | +$4.29K | ﹤0.01% | 5021 |
|
|
2024
Q1 | – | Sell |
-6,400
| Closed | -$50.9K | – | 5125 |
|
|
2023
Q4 | $50.9K | Hold |
6,400
| – | – | ﹤0.01% | 4774 |
|
|
2023
Q3 | $41.4K | Hold |
6,400
| – | – | ﹤0.01% | 3947 |
|
|
2023
Q2 | $39.6K | Hold |
6,400
| – | – | ﹤0.01% | 3930 |
|
|
2023
Q1 | $24.6K | Buy |
+6,400
| New | +$23.4K | ﹤0.01% | 4619 |
|
Barclays's CNTA Position: Q2 2026 in Review
Barclays sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 6,922 shares — an estimated $275K sold.
Barclays first reported a position in CNTA in Q1 2023 and held it in 11 quarters. The position peaked at $549K in Q1 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Barclays reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Barclays sold 6,922 Centessa Pharmaceuticals shares in Q2 2026, an estimated $275K.
- Barclays first reported a position in Centessa Pharmaceuticals in Q1 2023 and held it in 11 quarters.
- Barclays's Centessa Pharmaceuticals position peaked at $549K in Q1 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.